Gene therapy for prostate cancer: Current status and future prospects

Journal of Urology

Volumn 166, Issue 4, 2001, Pages 1220-1233

  Jacobs, Stephen C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; Prostate; Prostatic neoplasms

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ACICLOVIR; AMYGDALIN; ANGIOGENESIS INHIBITOR; AZOBENZENE DERIVATIVE; AZOBENZENE MUSTARD; CEPHALOSPORIN DERIVATIVE; CYTOSINE DEAMINASE; DAUNORUBICIN DERIVATIVE; DNA; FLUOROURACIL; GANCICLOVIR; GLUCOSE; GOLD; HYPOXANTHINE; LIPOSOME; METHOTREXATE DERIVATIVE; N [4 (ALPHA DEXTRO GALACTOPYRANOSYL)BENZYLOXYCARBONYL]DAUNORUBICIN; NITROGEN MUSTARD CEPHALOSPORIN; PHENYLENEDIAMINE DERIVATIVE; PHENYLENEDIAMINE MUSTARD; PHENYLENEDIAMINE MUSTARD CEPHALOSPORIN; PLASMID DNA; POLYMER; PROTEIN TYROSINE KINASE; RADIOISOTOPE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VINCA CEPHALOSPORIN;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANIMAL MODEL; APOPTOSIS; CLINICAL TRIAL; EXPRESSION VECTOR; GENE FUNCTION; GENE THERAPY; HERPES VIRUS; HUMAN; IMMUNOMODULATION; MALE; NONHUMAN; ONCOGENE; POXVIRUS; PRIORITY JOURNAL; PROSTATE CANCER; RETROVIRUS; REVIEW; SUICIDE GENE; TUMOR SUPPRESSOR GENE; VIRUS RECOMBINANT;

EID: 0034835307     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)65742-4     Document Type: Review

References (176)

1. Prostate-specific membrane antigen and other prostatic tumor markers on the horizon
2. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen
3. Relative activity and specificity of promoters from prostate-expressed genes
4. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer
5. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines
6. In vivo expression of prostate-specific adenoviral vectors in a canine model
7. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector
8. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer
9. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines
10. Transcriptionally regulated adenoviruses for prostate-specific gene therapy
11. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis
12. Gene therapy: Promises, problems and prospects
13. Targeting of cytokine gene expression to malignant melanoma cells using tissue specific promoter sequences
14. In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound
15. Direct gene transfer to mouse melanoma by intratumor injection of free DNA
16. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations
17. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice
18. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure
19. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer
20. Cationic lipid-mediated gene transfer: Current concepts
21. Nonviral gene therapy: Promises and challenges
22. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
23. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumour therapeutic efficacy
24. Sterically stabilised liposomes in cancer therapy and gene delivery
25. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions
26. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience
27. Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery
28. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine
29. Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery
30. PEGylated DNA/transferrin-PEI complexes: Reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery
31. In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer
32. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism
33. Reovirus therapy of tumors with activated Ras pathway
34. Human tumor cell modification by virus infection: An efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus
35. Evaluation of recombinant alphaviruses as vectors in gene therapy
36. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
37. Retroviral vectors
38. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
39. Development and application of adenoviral vectors for gene therapy of cancer
40. Strategies to adapt adenoviral vectors for targeted delivery
41. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy
42. The origin of adenovirus DNA replication: Minimal DNA sequence requirement in vivo
43. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
44. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015)
45. ONYX-015: Clinical data are encouraging
46. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
47. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts
48. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse
49. Adeno-associated viral vectors
50. Engineering herpes simplex virus vectors for gene transfer to neurons
51. HSV- 1 amplicon-1 vector: Simplicity and versatility
52. Experimental therapy of human glioma by means of a genetically engineered virus mutant
53. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase
54. An oncolytic herpes simplex virus type I selectively destroys diffuse liver metastases from colon carcinoma
55. Oncolytic viruses as novel anticancer agents: Turning one scourge against another
56. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
57. Attenuated multimutated herpes simplex virus- 1 for the treatment of malignant gliomas
58. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207
59. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207
60. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer
61. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases
62. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice
63. Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant
64. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation
65. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF
66. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth
67. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
68. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
69. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas
70. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer
71. Viral vector delivery in solid-state vehicles: Gene expression in a murine prostate cancer model
72. Cancer. p53, guardian of the genome
73. p53-Dependent cell cycle control: Response to genotoxic stress
74. p53 Oncogene mutations in human prostate cancer specimens
75. p53 Abnormalities in primary prostate cancer: Single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA
76. p53 In prostate cancer: Frequent expressed transition mutations
77. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer
78. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells
79. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model
80. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer
81. Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector
82. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer
83. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
84. Ad5CMVp53 gene therapy for locally advanced prostate cancer: Where do we stand?
85. Retinoblastoma gene mutations in primary human prostate cancer
86. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas
87. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein
88. Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb± mice
89. RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb± mice
90. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer
91. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer
92. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma
93. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence
94. p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways
95. Adenovirus p16 gene therapy for prostate cancer
96. Role of adhesion molecules in bladder cancer: An important part of the jigsaw
97. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: A preclinical study
98. Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model
99. Tumor-suppressive activity of CD66a in prostate cancer
100. Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection
101. Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells
102. Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2
103. Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde
104. Comparison of ras activation in prostate carcinoma in Japanese and American men
105. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization
106. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia
107. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
108. Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: A novel therapy in prostate cancer
109. Antisense c-myc retroviral vector suppresses established human prostate cancer
110. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model
111. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
112. Suppression of various human tumor cell lines by a dominant negative H-ras mutant
113. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice
114. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer
115. Design and testing of ribozymes for cancer gene therapy
116. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer
117. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells
118. Effective reversal of a transformed phenotype by retrovirus-mediated transfer of a ribozyme directed against mutant N-ras
119. A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow
120. Prodrug-activating systems in suicide gene therapy
121. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer
122. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models
123. In vivo gene therapy for prostate cancer: Preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors
124. Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: Changes in tumour cell proliferative activity
125. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer
126. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer
127. Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity
128. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer
129. Cytopathic effect of in situ gene therapy in prostate cancer
130. Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors
131. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
132. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer
133. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
134. The hallmarks of cancer
135. Tumor angiogenesis and endothelial cell modulatory factors
136. Tumor angiogenesis: Biology and therapeutic prospects
137. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
138. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
139. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
140. Angiostatin induces and sustains dormancy of human primary tumors in mice
141. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
142. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
143. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases
144. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth
145. Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice
146. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
147. Thyroid iodine transport
148. Treatment of prostate cancer by radioiodine after tissue-specific expression of the sodium iodide symporter
149. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy
150. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer
151. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis
152. Intracellular fas ligand expression causes fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis
153. Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene
154. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth
155. Apoptosis or necrosis for tumor immunotherapy: What's in a name?
156. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma
157. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
158. Molecular characterization of defective antigen processing in human prostate cancer
159. Fas ligand is constitutively secreted by prostate cancer cells in vitro
160. Fas-mediated apoptosis in human prostatic carcinoma cell lines
161. Immunotherapy for cancer by direct gene transfer into tumors
162. Experimental and clinical studies of cytokine gene-modified tumor cells
163. T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector
164. The case for therapeutic vaccines. Melanoma Res
165. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component
166. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer
167. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: Implications for tolerance and immunotherapy
168. Demonstration of a rational strategy for human prostate cancer gene therapy
169. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
170. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial
171. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines
172. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model
173. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells
174. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer
175. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta
176. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides